Search
forLearn
5 / 801 resultslearn ACETYL TETRAPEPTIDE-2
learn multipeptides
learn molybdenum
learn microbiota modulator
Research
5 / 199 resultsresearch Bioengineering a humanized acne microenvironment model: Proteomics analysis of host responses to Propionibacterium acnes infection in vivo
A new model helps study acne and test treatments.
research Inflammatory and Anti-Inflammatory Parameters in PCOS Patients Depending on Body Mass Index: A Case-Control Study
PCOS causes inflammation regardless of body weight.
research Assessment of chemokines MIP-1α and MIP-1 βin Iraqi women with polycystic ovarian syndrome
PCOS is linked to low-grade chronic inflammation.
research 361 p120-catenin regulates epidermal inflammation in a cadherin-dependent manner
p120-catenin helps control skin inflammation by regulating cadherin levels.
research Topical SCD-153, a 4-methyl itaconate prodrug, for the treatment of alopecia areata
SCD-153 shows promise as an effective topical treatment for alopecia areata.
Community Join
5 / 1000+ resultscommunity This, and the UCLA molecule(linked article in comments)…I have great hopes
Oleic acid and ethanol are being considered for hair regrowth, with some users planning to self-experiment. There is skepticism about their effectiveness, and ongoing use of treatments like finasteride and minoxidil is mentioned.
community Split-scalp pilot study to evaluate effectiveness of Minoxidil 0.5% MMP® versus Topical Minoxidil 5% in the treatment of Female Pattern Hair Loss
Minoxidil 0.5% MMP® showed better results in parietal-vertex regions for less advanced female pattern hair loss compared to Minoxidil 5%. MMP® with Minoxidil can improve the quality of life for these patients.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community HMI 115 Phase 1 update: Changes to clinicaltrials.gov page
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
community Pelage PP405 Phase 2a completed.
Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.